name nAnno nOverlap fc zscore pvalue adjp or CIl CIu
path:hsa04140 Autophagy - animal 128 9 6.87 6.82 5.2e-06 5e-04 8.27 3.52 17.3
path:hsa04931 Insulin resistance 107 8 7.31 6.69 1.2e-05 0.00055 8.72 3.5 19
path:hsa04211 Longevity regulating pathway 89 7 7.68 6.46 3e-05 0.00073 9.08 3.4 20.7
path:hsa04722 Neurotrophin signaling pathway 119 8 6.57 6.23 2.5e-05 0.00073 7.76 3.13 16.8
path:hsa04068 FoxO signaling pathway 131 8 5.97 5.84 5e-05 0.00097 6.99 2.82 15.1
path:hsa04024 cAMP signaling pathway 198 9 4.44 5 0.00017 0.0027 5.15 2.21 10.7
path:hsa05223 Non-small cell lung cancer 58 5 8.42 5.77 0.00029 0.004 9.76 2.94 25.4
path:hsa04213 Longevity regulating pathway - multiple species 62 5 7.88 5.53 4e-04 0.0048 9.07 2.74 23.5
path:hsa05231 Choline metabolism in cancer 99 6 5.92 5.02 0.00049 0.0052 6.74 2.32 16.1
path:hsa04917 Prolactin signaling pathway 70 5 6.98 5.11 7e-04 0.0064 7.94 2.41 20.5
path:hsa04668 TNF signaling pathway 108 6 5.43 4.72 0.00078 0.0064 6.14 2.12 14.6
path:hsa04150 mTOR signaling pathway 150 7 4.56 4.48 8e-04 0.0064 5.16 1.96 11.6
path:hsa04930 Type II diabetes mellitus 46 4 8.5 5.19 0.0012 0.0078 9.71 2.46 28
path:hsa01521 EGFR tyrosine kinase inhibitor resistance 79 5 6.18 4.71 0.0012 0.0078 6.97 2.13 17.9
path:hsa04144 Endocytosis 260 9 3.38 3.98 0.0012 0.0078 3.84 1.66 7.92
path:hsa04152 AMPK signaling pathway 120 6 4.89 4.37 0.0013 0.0081 5.48 1.9 13
path:hsa05213 Endometrial cancer 50 4 7.82 4.92 0.0016 0.0082 8.86 2.25 25.4
path:hsa05222 Small cell lung cancer 84 5 5.82 4.52 0.0016 0.0082 6.52 1.99 16.7
path:hsa04012 ErbB signaling pathway 86 5 5.68 4.44 0.0018 0.0082 6.36 1.94 16.3
path:hsa04611 Platelet activation 123 6 4.77 4.29 0.0015 0.0082 5.34 1.85 12.6
path:hsa04380 Osteoclast differentiation 127 6 4.62 4.18 0.0018 0.0082 5.16 1.79 12.2
path:hsa04360 Axon guidance 175 7 3.91 3.96 0.002 0.0085 4.37 1.66 9.77
path:hsa04666 Fc gamma R-mediated phagocytosis 90 5 5.43 4.3 0.0022 0.0091 6.06 1.85 15.4
path:hsa05221 Acute myeloid leukemia 55 4 7.11 4.62 0.0023 0.0092 7.99 2.04 22.7
path:hsa01522 Endocrine resistance 95 5 5.14 4.14 0.0028 0.0099 5.72 1.75 14.5
path:hsa04914 Progesterone-mediated oocyte maturation 96 5 5.09 4.1 0.0029 0.0099 5.65 1.73 14.4
path:hsa04910 Insulin signaling pathway 138 6 4.25 3.92 0.0027 0.0099 4.72 1.64 11.1
path:hsa05418 Fluid shear stress and atherosclerosis 139 6 4.22 3.9 0.0028 0.0099 4.69 1.63 11.1
path:hsa05210 Colorectal cancer 60 4 6.51 4.36 0.0032 0.01 7.27 1.86 20.6
path:hsa04070 Phosphatidylinositol signaling system 97 5 5.04 4.07 0.003 0.01 5.59 1.71 14.2
path:hsa05212 Pancreatic cancer 64 4 6.11 4.17 0.004 0.012 6.78 1.74 19.1
path:hsa05211 Renal cell carcinoma 65 4 6.01 4.13 0.0043 0.012 6.67 1.71 18.8
path:hsa05142 Chagas disease (American trypanosomiasis) 102 5 4.79 3.92 0.0037 0.012 5.3 1.63 13.5
path:hsa04620 Toll-like receptor signaling pathway 104 5 4.7 3.86 0.0041 0.012 5.19 1.59 13.2
path:hsa04664 Fc epsilon RI signaling pathway 67 4 5.83 4.04 0.0047 0.013 6.46 1.66 18.2
path:hsa04960 Aldosterone-regulated sodium reabsorption 37 3 7.92 4.29 0.0062 0.015 8.87 1.7 29.3
path:hsa00562 Inositol phosphate metabolism 71 4 5.5 3.88 0.0058 0.015 6.07 1.56 17
path:hsa05220 Chronic myeloid leukemia 71 4 5.5 3.88 0.0058 0.015 6.07 1.56 17
path:hsa04725 Cholinergic synapse 112 5 4.36 3.65 0.0056 0.015 4.8 1.48 12.1
path:hsa04973 Carbohydrate digestion and absorption 44 3 6.66 3.83 0.01 0.024 7.35 1.42 24
path:hsa04728 Dopaminergic synapse 130 5 3.76 3.23 0.01 0.024 4.09 1.26 10.3
path:hsa05160 Hepatitis C 131 5 3.73 3.21 0.011 0.024 4.06 1.25 10.2
path:hsa05215 Prostate cancer 87 4 4.49 3.33 0.012 0.026 4.89 1.26 13.6
path:hsa04550 Signaling pathways regulating pluripotency of stem cells 139 5 3.51 3.05 0.014 0.03 3.81 1.18 9.6
path:hsa04923 Regulation of lipolysis in adipocytes 54 3 5.43 3.32 0.018 0.033 5.9 1.15 19
path:hsa04713 Circadian entrainment 96 4 4.07 3.08 0.016 0.033 4.4 1.14 12.2
path:hsa04750 Inflammatory mediator regulation of TRP channels 97 4 4.03 3.06 0.017 0.033 4.35 1.13 12.1
path:hsa04915 Estrogen signaling pathway 98 4 3.99 3.03 0.018 0.033 4.31 1.12 11.9
path:hsa04066 HIF-1 signaling pathway 99 4 3.95 3 0.018 0.033 4.26 1.1 11.8
path:hsa04933 AGE-RAGE signaling pathway in diabetic complications 99 4 3.95 3 0.018 0.033 4.26 1.1 11.8
path:hsa05161 Hepatitis B 144 5 3.39 2.95 0.016 0.033 3.67 1.14 9.24
path:hsa04932 Non-alcoholic fatty liver disease (NAFLD) 149 5 3.28 2.86 0.018 0.033 3.54 1.1 8.91
path:hsa05205 Proteoglycans in cancer 203 6 2.89 2.78 0.017 0.033 3.13 1.09 7.33
path:hsa04660 T cell receptor signaling pathway 103 4 3.79 2.91 0.021 0.036 4.09 1.06 11.3
path:hsa04810 Regulation of actin cytoskeleton 212 6 2.77 2.66 0.021 0.036 2.99 1.05 7
path:hsa04370 VEGF signaling pathway 59 3 4.97 3.11 0.022 0.037 5.37 1.05 17.2
path:hsa04630 Jak-STAT signaling pathway 156 5 3.13 2.74 0.021 0.037 3.38 1.04 8.47
path:hsa04151 PI3K-Akt signaling pathway 341 8 2.29 2.49 0.022 0.037 2.5 1.02 5.3
path:hsa05214 Glioma 64 3 4.58 2.93 0.027 0.044 4.93 0.964 15.7
path:hsa05230 Central carbon metabolism in cancer 65 3 4.51 2.89 0.029 0.044 4.85 0.949 15.5
path:hsa04670 Leukocyte transendothelial migration 112 4 3.49 2.7 0.027 0.044 3.74 0.972 10.3
path:hsa04724 Glutamatergic synapse 114 4 3.43 2.66 0.029 0.044 3.67 0.954 10.1
path:hsa04014 Ras signaling pathway 227 6 2.58 2.47 0.028 0.044 2.78 0.973 6.5
path:hsa05031 Amphetamine addiction 68 3 4.31 2.79 0.032 0.046 4.62 0.906 14.7
path:hsa04920 Adipocytokine signaling pathway 69 3 4.25 2.76 0.033 0.046 4.55 0.892 14.5
path:hsa05218 Melanoma 69 3 4.25 2.76 0.033 0.046 4.55 0.892 14.5
path:hsa04919 Thyroid hormone signaling pathway 116 4 3.37 2.62 0.031 0.046 3.61 0.937 9.95
path:hsa04071 Sphingolipid signaling pathway 118 4 3.31 2.58 0.032 0.046 3.54 0.921 9.77
path:hsa05164 Influenza A 173 5 2.82 2.47 0.032 0.046 3.03 0.938 7.58
path:hsa05167 Kaposi's sarcoma-associated herpesvirus infection 173 5 2.82 2.47 0.032 0.046 3.03 0.938 7.58
path:hsa04662 B cell receptor signaling pathway 70 3 4.19 2.73 0.034 0.047 4.48 0.879 14.3
